Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1647-1655

  Luetkens, Tim ^a   Schafhausen, Phillipe ^a   Uhlich, Frederike ^a   Stasche, Tim ^a   Akbulak, Ruken ^a   Bartels, Britta M ^a   Hildebrandt, York ^a   Gontarewicz, Arthur ^a   Kobold, Sebastian ^a   Meyer, Sabrina ^a   Gordic, Maja ^a   Bartels, Katrin ^a   Lajmi, Nesrine ^a   Cao, Yanran ^a   Kröger, Nicolaus ^a   Bokemeyer, Carsten ^a   Brümmendorf, Tim H ^b   Atanackovic, Djordje ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cancer testis antigens; Chronic myeloid leukemia; Imatinib; PRAME; Tumor immunology

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; IMATINIB; PRAME PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNITY, HUMORAL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES;

EID: 77956523154     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.039     Document Type: Article

References (59)

1. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
2. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
3. Hughes T.P., Kaeda J., Branford S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
4. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
5. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
6. Litzow M.R. Imatinib resistance: obstacles and opportunities. Arch Pathol Lab Med 2006, 130:669-679.
7. Quintas-Cardama A., Cortes J.E. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc 2006, 81:973-988.
8. Branford S., Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006, 125:93-106.
9. Grigg A., Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant 2006, 12:795-807.
10. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
11. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
12. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
13. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002, 100:397-405.
14. Drobyski W.R., Hessner M.J., Klein J.P., et al. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 1999, 94:434-441.
15. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32.
16. Chambost H., van Baren N., Brasseur F., Olive D. MAGE-A genes are not expressed in human leukemias. Leukemia 2001, 15:1769-1771.
17. Chambost H., Brasseur F., Coulie P., et al. A tumour-associated antigen expression in human haematological malignancies. Br J Haematol 1993, 84:524-526.
18. Lim S.H., Austin S., Owen-Jones E., Robinson L. Expression of testicular genes in haematological malignancies. Br J Cancer 1999, 81:1162-1164.
19. Adams S.P., Sahota S.S., Mijovic A., et al. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002, 16:2238-2242.
20. Paydas S., Tanriverdi K., Yavuz S., Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: clinical importance and review of the literature. Leuk Res 2007, 31:365-369.
21. Rezvani K., Yong A.S., Tawab A., et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009, 113:2245-2255.
22. Quintarelli C., Dotti G., De Angelis B., et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008, 112:1876-1885.
23. Weber J., Salgaller M., Samid D., et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. Cancer Res 1994, 54:1766-1771.
24. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res 2006, 4:339-349.
25. Sigalotti L., Fratta E., Coral S., et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res 2004, 64:9167-9171.
26. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
27. Atanackovic D., Hildebrandt Y., Jadczak A., et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2009.
28. Stockert E., Jager E., Chen Y.T., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998, 187:1349-1354.
29. Kuendgen A., Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008, 87:601-611.
30. Vanhaecke T., Papeleu P., Elaut G., Rogiers V. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Curr Med Chem 2004, 11:1629-1643.
31. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005, 45:495-528.
32. Proto-Siqueira R., Figueiredo-Pontes L.L., Panepucci R.A., et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 2006, 30:1333-1339.
33. Kilpinen S., Autio R., Ojala K., et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008, 9:R139.
34. Ortmann C.A., Eisele L., Nuckel H., et al. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann Hematol 2008, 87:809-818.
35. Schenk T., Stengel S., Goellner S., Steinbach D., Saluz H.P. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies. Genes Chromosomes Cancer 2007, 46:796-804.
36. Gale R.P., Hehlmann R., Zhang M.J., et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 1998, 91:1810-1819.
37. van Rhee F., Szydlo R.M., Hermans J., et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997, 20:553-560.
38. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
39. Matsushita M., Ikeda H., Kizaki M., et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001, 112:916-926.
40. Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005, 79:257-261.
41. van Baren N., Chambost H., Ferrant A., et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998, 102:1376-1379.
42. Greiner J., Ringhoffer M., Simikopinko O., et al. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol 2000, 28:1413-1422.
43. Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005, 122:835-847.
44. Oehler V.G., Guthrie K.A., Cummings C.L., et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009, 114:3299-3308.
45. Radich J.P., Dai H., Mao M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
46. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103:4010-4022.
47. Shet A.S., Jahagirdar B.N., Verfaillie C.M. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002, 16:1402-1411.
48. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005, 103:1659-1669.
49. Yang B., Wu J., Maddodi N., Ma Y., Setaluri V., Longley B.J. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase. J Invest Dermatol 2007, 127:2123-2128.
50. Epping M.T., Hart A.A., Glas A.M., Krijgsman O., Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer 2008, 99:398-403.
51. Partheen K., Levan K., Osterberg L., et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 2008, 123:2130-2137.
52. Old L.J. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immun 2001, 1:1.
53. Reuschenbach M., von Knebel Doeberitz M., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009, 58:1535-1544.
54. Paniagua R.T., Sharpe O., Ho P.P., et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006, 116:2633-2642.
55. Sadanaga A., Nakashima H., Masutani K., et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 2005, 52:3987-3996.
56. Appel S., Boehmler A.M., Grunebach F., et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004, 103:538-544.
57. Seggewiss R., Lore K., Greiner E., et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 105:2473-2479.
58. Sinai P., Berg R.E., Haynie J.M., Egorin M.J., Ilaria R.L., Forman J. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo. J Immunol 2007, 178:2028-2037.
59. Mumprecht S., Matter M., Pavelic V., Ochsenbein A.F. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 2006, 108:3406-3413.